Patents by Inventor Tuyen M. Nguyen

Tuyen M. Nguyen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRION PROTEIN (PRNP) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240124882
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a prion protein (PRNP) gene, as well as methods of inhibiting expression of a PRNP gene and methods of treating subjects having a PRNP-associated disease or disorder, e.g., Prion diseases, using such dsRNAi agents and compositions.
    Type: Application
    Filed: August 22, 2023
    Publication date: April 18, 2024
    Inventors: Haiyan Peng, Bret Lee Bostwick, James D. McIninch, Mark K. Schlegel, Adam Castoreno, Tuyen M. Nguyen
  • COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES
    Publication number: 20240110180
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.
    Type: Application
    Filed: May 19, 2023
    Publication date: April 4, 2024
    Inventors: Brian Bettencourt, Kevin Fitzgerald, Stuart Milstein, Martin A. Maier, Klaus Charisse, Kallanthottathil G. Rajeev, Satyanarayana Kuchimanchi, Muthiah Manoharan, Tuyen M. Nguyen
  • Peptide modulators of the ?PKC interaction with the d subunit of FFo ATP synthase/ATPase and uses thereof
    Patent number: 8754051
    Abstract: The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF1Fo protein may also have efficacies in these disease states and therefore all peptides shown in the Figures of this application (combined with the human immunodeficiency virus (HIV)-Tat protein transduction, cytochrome oxidase subunit IV (COIV) mitochondrial targeting and Flag domains) are included for their efficacies in these conditions.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 17, 2014
    Assignee: Georgia Regents Research Institute, Inc.
    Inventors: John A. Johnson, Tiffany Tuyen M. Nguyen, Mourad Ogbi
  • Peptide Modulators of the deltaPKC Interaction with the d Subunit of F1F0 ATP Synthase/ATPase and Uses Thereof
    Publication number: 20120283182
    Abstract: The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1Fo ATP synthase (dF1Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF1Fo protein may also have efficacies in these disease states and therefore all peptides shown in the Figures of this application (combined with the HIV-Tat protein transduction, COIV mitochondrial targeting and Flag domains) are included for their efficacies in these conditions.
    Type: Application
    Filed: February 21, 2012
    Publication date: November 8, 2012
    Inventors: John A. Johnson, Tiffany Tuyen M. Nguyen, Mourad Ogbi